Core Viewpoint - ATS is expected to report a year-over-year decline in earnings due to lower revenues, with the earnings report set for August 8, 2024, being a significant factor for stock price movement [1] Group 1: Earnings Estimates - ATS is projected to post quarterly earnings of $0.40 per share, reflecting a year-over-year decrease of 21.6% [2] - Revenues for ATS are anticipated to be $507.18 million, down 9.6% from the same quarter last year [2] Group 2: Estimate Revisions - The consensus EPS estimate for ATS has been revised down by 0.61% over the last 30 days, indicating a bearish sentiment among analysts [3] - The Most Accurate Estimate for ATS is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -6.33% [6] Group 3: Earnings Surprise Prediction - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [5] - ATS currently holds a Zacks Rank of 4, making it challenging to predict an earnings beat [7] Group 4: Historical Performance - In the last reported quarter, ATS had an earnings surprise of +17.07%, with actual earnings of $0.48 per share compared to an expected $0.41 [8] - Over the past four quarters, ATS has beaten consensus EPS estimates two times [8] Group 5: Industry Comparison - Helios Technologies, another player in the same industry, is expected to report earnings of $0.61 per share, indicating a year-over-year decline of 24.7% [10] - Helios Technologies has a Zacks Rank of 5, making it difficult to predict an earnings beat, despite a recent revision of the EPS estimate being 0.8% higher [10]

 Neumifil delivers statistically significant reductions in influenza symptomatic infection rate, symptom severity and viral loadStrategy to advance clinical development of Neumifil to be based on these positive data and pre-clinical data package demonstrating Neumifil’s activity against a broad range of viruses St Andrews, UK – 23nd May 2024 - Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respir ...

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting Additional KT-621 preclinical data was also featured in a poster presentation at Digestive Disease Week KT-621 expected to start Phase 1 in the second half of 2024,with Phase 1 data in the first half of 2025 WATERTOWN, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage bio ...

JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held from May 17-22, 2024 in San Diego. InflaRx is presenting a poster at the thematic poster session at the ATS conference today from 11:30 AM PT / 2:30 PM ET to 1:15 PM PT / 4:15 PM ET. The poster is titled, “Vilobelima ...

Core Insights - The NOTUS phase 3 study confirms Dupixent's efficacy in reducing COPD exacerbations by 34% and improving lung function, marking it as a potential first new treatment for COPD in over a decade [1][2][3] Study Results - Dupixent significantly reduced moderate or severe COPD exacerbations by 34% over 52 weeks compared to placebo (p<0.001), meeting the primary endpoint [2][3] - Patients on Dupixent showed more than two times greater improvement in lung function (pre-bronchodilator FEV1) at 12 weeks (139 mL vs. 57 mL; p<0.001) and maintained improvement at week 52 (115 mL vs. 54 mL; p=0.018) [2][3] - Health-related quality of life improvements and reductions in respiratory symptom severity were also observed, although these were numerically greater rather than statistically significant [2] Safety Profile - The overall rates of adverse events (AEs) were similar between Dupixent (67%) and placebo (66%) [3] - Common AEs for Dupixent included COVID-19 (9.4%), nasopharyngitis (6.2%), and headache (7.5%), while COPD-related AEs were more common in the placebo group (7.8%) [3] Regulatory Status - Dupixent is under Priority Review by the US FDA for use in uncontrolled COPD with type 2 inflammation, with a target action date of June 27, 2024 [3] - Regulatory submissions are also under review in the EU and China, with ongoing discussions with other regulatory authorities [3] Background on COPD - COPD is a progressive respiratory disease with significant health and economic burdens, affecting approximately 300,000 people in the US with uncontrolled symptoms and type 2 inflammation [5]

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD TARRYTOWN, N.Y. and PARIS, May 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: ...

Late-Breaking Results From the Phase 2a COURSE Trial Illustrate Tezspire's Impact on COPD Exacerbations in Patients With a Broad Range of Eosinophil Levels THOUSAND OAKS, Calif., May 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, ...

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When:          May 17–22, 2024Where:         San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101                       Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101Research:     26 ResMed-supported abstracts will be presented at ATS. Full list below. Highlights:Innovation Hub:     Healthcare of Today, Looking Towards Tomorrow: Digital Innovations and Patient CentricityBooth #1442:            Featuring ResMed’s late ...

Financial Performance - Revenues for Q4 2024 increased 8.3% year over year to $791.5 million, with a year-to-date revenue increase of 17.7% to $3,032.9 million[3][4]. - Net income for Q4 2024 was $48.5 million, a 63.9% increase from $29.6 million in Q4 2023, while year-to-date net income rose 52.1% to $194.2 million[3][4]. - Adjusted EBITDA for Q4 2024 was $115.8 million, a 2.0% decrease from $118.2 million a year ago, with year-to-date adjusted EBITDA increasing 17.3% to $470.6 million[3][4]. - Total revenues for fiscal 2024 were reported at $3,032.9 million, a 17.6% increase from $2,577.4 million in fiscal 2023[59]. - Adjusted EBITDA for fiscal 2024 was $470.6 million, compared to $401.2 million in fiscal 2023, reflecting a year-over-year increase of approximately 17.3%[39]. - Net income for the fiscal year 2024 was $194.2 million, a significant increase of 52.1% from $127.7 million in fiscal 2023[59]. - Earnings from operations for Q4 2024 were $74.8 million, up from $51.9 million in Q4 2023, representing a year-over-year increase of approximately 43%[38]. - The company reported a basic EPS of $0.49 for Q4 2024, compared to $0.32 for Q4 2023, representing an increase of 53.1%[44]. - Earnings per share attributable to shareholders increased to $1.98 for fiscal 2024, up from $1.39 in fiscal 2023, representing a growth of 42.4%[59]. Order Bookings and Backlog - Order Bookings for Q4 2024 were $791 million, a 7.3% increase year over year, while year-to-date Order Bookings totaled $2,891 million, down 11.2% from the previous year[3][4][16]. - Order Backlog at the end of Q4 2024 was $1,793 million, a decrease of 16.7% compared to $2,153 million at the end of Q4 2023[6][18]. - The Order Backlog stands at $1,793 million, with an expected revenue conversion rate of 36% to 40% in Q1 fiscal 2025[22]. - Approximately $200 million of Order Backlog related to an EV customer was delayed, with a reduction of $50 million in the fourth quarter due to scope changes[22]. - Total order backlog as of March 31, 2024, is $1,793 million, down from $2,153 million in the previous year, representing a decrease of 16.7%[40]. - Total order bookings for the fiscal year 2024 amount to $2,891 million, a decline of 11.2% from $3,256 million in fiscal year 2023[41]. Acquisitions and Strategic Focus - The company announced the acquisition of Paxiom Group, expected to close in Q3 2024, enhancing its packaging solutions portfolio[7]. - The company acquired IT.ACA on January 1, 2024, strengthening its automation system integration capabilities in southern Europe[8]. - The company aims to achieve organic revenue growth and identify strategic acquisition opportunities to access attractive end-markets[23]. - The company anticipates future growth through organic expansion and acquisitions, with a focus on emerging markets and digitalization capabilities[69]. Market Trends and Challenges - The life sciences market remains strong, with expected revenues from GLP-1 drugs projected to become a high single-digit percentage of total revenues in the coming years[19]. - Customers are exercising caution in investment and spending, but underlying trends such as rising labor costs and production reshoring remain favorable for the company's solutions[21]. - The company is focused on clean energy applications, including solutions for nuclear power plant refurbishment and grid battery storage[20][21]. - There are concerns regarding the impact of macroeconomic factors such as inflation, supply chain disruptions, and interest rate changes on the company's operations[70]. - The company acknowledges risks related to customer concentration and potential impacts from regional or global conflicts on market performance[71]. - The company is facing challenges in securing labor and materials, which may affect its ability to expand operations organically or through acquisitions[71]. - There is uncertainty regarding the conversion of sales funnel to order bookings due to competitive factors and customer needs[72]. - The company is monitoring the potential impact of changes in accounting standards on its financial statements[73]. Financial Position and Cash Flow - Cash and cash equivalents increased to $170.2 million as of March 31, 2024, compared to $159.9 million in the previous year, representing a growth of 8.1%[50]. - Free cash flow for Q4 2024 was $(16.3) million, a decrease from $47.9 million in Q4 2023, reflecting a decline of 134.0%[51]. - Cash flows provided by operating activities decreased significantly to $20,780 from $127,800, a decline of 83.8%[61]. - Cash flows used in investing activities increased to $(341,785) from $(109,022), representing a rise of 213.5%[61]. - Cash flows provided by financing activities surged to $330,724 from $4,882, an increase of 6,635.5%[61]. - The company reported cash income taxes paid of $49,511, down from $58,398, a decrease of 15.9%[61]. - The company’s total bank indebtedness decreased to $(1,527) from $3,399, indicating improved financial leverage[61]. - The net debt to adjusted EBITDA ratio improved to 2.4x as of March 31, 2024, down from 2.7x in the previous year[50]. - The company reported a debt-to-equity ratio of 0.79:1 as of March 31, 2024, improved from 1.18:1 in the previous year[55]. - The company’s long-term debt stood at $1,171.8 million as of March 31, 2024, slightly up from $1,155.7 million in the previous year[50]. - Non-cash working capital as a percentage of trailing six-month revenues increased to 19.0% as of March 31, 2024, compared to 10.1% in the previous year[49]. - Non-cash working capital levels as a percentage of revenues may fluctuate due to timing and nature of order bookings and payment terms[72].

Financial Data and Key Metrics Changes - ATS reported record revenues of $792 million in Q4, an 8% increase from the previous year, with full-year revenues up 18% [8][19] - Adjusted earnings from operations for Q4 were $96 million, with full-year adjusted earnings at $398 million, a 16% increase compared to fiscal '23 [8][20] - The order bookings for Q4 were $791 million, a 7.3% increase year-over-year, with full-year bookings totaling $2.9 billion [7][18] Business Line Data and Key Metrics Changes - Life Sciences saw a backlog of $871 million, up 14% year-over-year, driven by demand for autoinjector assembly and automated pharmacy solutions [8][9] - Transportation backlog was $425 million, reflecting ongoing execution of large programs, but with expected pressure on EV revenues [9][10] - Food & Beverage bookings were strong in Q4, with an ending backlog of $230 million, supported by seasonal variations [10][11] Market Data and Key Metrics Changes - The Life Sciences market remains robust, with a strong opportunity funnel driven by increased demand for GLP-1 drugs and wearable devices [9][15] - The Transportation market is experiencing short-term uncertainty, with smaller opportunities in the near term compared to previous years [10][18] - The Energy market is focused on refurbishing existing nuclear reactors, with new projects being approved [11] Company Strategy and Development Direction - ATS is advancing its value creation strategy through acquisitions, having completed four in fiscal '24, including the recent acquisition of Paxiom [6][14] - The company is committed to innovation, increasing its patent portfolio by nearly 10% over the last year [6][7] - ATS is focused on driving improvements through its ABM culture, emphasizing continuous improvement and operational efficiency [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to offset expected lower revenues from EV with growth in other markets, particularly Life Sciences [20][78] - The backlog remains strong at $1.8 billion, providing good revenue visibility for fiscal '25 [8][24] - Management noted improvements in supply chain lead times and ongoing efforts to manage material cost pressures [21][22] Other Important Information - ATS has been active in its share buyback program, repurchasing over 1 million shares for $45 million [7][24] - The company incurred $6.6 million in restructuring costs in Q4, totaling $22.8 million for the full year, aimed at cost reductions to support growth [22][23] - ATS was recognized as one of Southwestern Ontario's Top Employers for 2024, highlighting its commitment to employee engagement [16] Q&A Session Summary Question: Impact of EV program reduction - Management confirmed that customers are responsible for compensating ATS up until the point of work cancellation, and they expect to recover working capital from the cancellation [30] Question: Potential further reductions in EV demand - Management does not expect further cancellations, noting that the descoped portion was in the early design phase [32] Question: Working capital concerns - Management indicated that milestone payments are expected to normalize working capital levels in the upcoming quarters [34] Question: Revenue outlook excluding EV - Management clarified that the exclusion of EV from revenue expectations is due to timing uncertainty, but they remain optimistic about growth in other areas [38] Question: Autoinjector revenue ramp - Management expects autoinjector revenues to increase from low single-digits to high single-digits over the next several years [45] Question: Free cash flow expectations - Management indicated that working capital impacts from EV will improve as milestones are reached in the second half of the fiscal year [48] Question: Adjusted EBIT margin target - Management reaffirmed the target for a 15% adjusted EBIT margin, emphasizing ongoing initiatives to drive efficiency [50] Question: Backlog changes - Management explained that the decline in backlog was primarily due to the EV cancellation, along with some normal course scope changes [66] Question: 2025 sales outlook - Management indicated that they expect to offset declines in EV sales with growth in other markets, particularly Life Sciences [78]